Home » Stocks » KYMR

Kymera Therapeutics, Inc. (KYMR)

Stock Price: $77.51 USD -3.79 (-4.66%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $77.50 -0.01 (-0.01%) Jan 15, 4:48 PM
Market Cap 3.45B
Revenue (ttm) 23.08M
Net Income (ttm) -44.42M
Shares Out 20.68M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $77.51
Previous Close $81.30
Change ($) -3.79
Change (%) -4.66%
Day's Open 80.99
Day's Range 76.14 - 84.57
Day's Volume 79,234
52-Week Range 26.10 - 87.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 days ago

Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome. The company IPO...

GlobeNewsWire - 1 week ago

WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule...

GlobeNewsWire - 1 month ago

WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecul...

GlobeNewsWire - 1 month ago

WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecul...

GlobeNewsWire - 1 month ago

WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutic...

GlobeNewsWire - 2 months ago

WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutic...

GlobeNewsWire - 2 months ago

Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi

GlobeNewsWire - 2 months ago

WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule...

Seeking Alpha - 3 months ago

Kymera reports positive data for RAK4 degrader, KT-474.

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small mo...

GlobeNewsWire - 3 months ago

Data to be presented at the 5 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeu...

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeu...

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeut...

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeut...

Seeking Alpha - 4 months ago

U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week

Other stocks mentioned: FIIIU, HRMY, NNOX
GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeut...

About KYMR

Kymera Therapeutics, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and... [Read more...]

Industry
Biotechnology
IPO Date
Aug 21, 2020
CEO
Dr. Nello Mainolfi M.D., Ph.D.
Employees
64
Stock Exchange
NASDAQ
Ticker Symbol
KYMR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 72.00, which is a decrease of -7.11% from the latest price.

Price Target
$72.00
(-7.11% downside)
Analyst Consensus: Buy